Vyome Holdings, Inc. (HIND) - Total Liabilities
Based on the latest financial reports, Vyome Holdings, Inc. (HIND) has total liabilities worth $1.86 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Vyome Holdings, Inc. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Vyome Holdings, Inc. - Total Liabilities Trend (2003–2025)
This chart illustrates how Vyome Holdings, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Vyome Holdings, Inc..
Vyome Holdings, Inc. Competitors by Total Liabilities
The table below lists competitors of Vyome Holdings, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Torrent Capital Ltd
V:TORR
|
Canada | CA$1.42 Million |
|
Immo-Zenobe Gramme SA
BR:ZEN
|
Belgium | €8.06 Million |
|
BIT MINING C.A SP.ADR 100
F:50C0
|
Germany | €14.82 Million |
|
Acrinova AB
ST:ACRI-A
|
Sweden | Skr453.97 Million |
|
BALAXI PHARMACEUTICALS LIMITED
NSE:BALAXI
|
India | Rs879.53 Million |
|
Wahana Pronatural
JK:WAPO
|
Indonesia | Rp98.34 Billion |
|
Izoblok
WAR:IZB
|
Poland | zł213.54 Million |
|
GMV Minerals Inc
V:GMV
|
Canada | CA$71.56K |
Liability Composition Analysis (2003–2025)
This chart breaks down Vyome Holdings, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See HIND equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vyome Holdings, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vyome Holdings, Inc. (2003–2025)
The table below shows the annual total liabilities of Vyome Holdings, Inc. from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.74 Million | -45.80% |
| 2024-12-31 | $5.05 Million | +24.16% |
| 2023-12-31 | $4.06 Million | -46.55% |
| 2022-12-31 | $7.60 Million | -7.23% |
| 2021-12-31 | $8.20 Million | -67.51% |
| 2020-12-31 | $25.23 Million | +62.24% |
| 2019-12-31 | $15.55 Million | +6.43% |
| 2018-12-31 | $14.61 Million | +18.42% |
| 2017-12-31 | $12.34 Million | +200.78% |
| 2016-12-31 | $4.10 Million | -48.17% |
| 2015-12-31 | $7.91 Million | +2.49% |
| 2014-12-31 | $7.72 Million | -34.05% |
| 2013-12-31 | $11.71 Million | -17.66% |
| 2012-12-31 | $14.22 Million | +14.27% |
| 2011-12-31 | $12.44 Million | +38.59% |
| 2010-12-31 | $8.98 Million | -15.55% |
| 2009-12-31 | $10.63 Million | -36.98% |
| 2008-12-31 | $16.87 Million | +22.55% |
| 2007-12-31 | $13.77 Million | +83.83% |
| 2006-12-31 | $7.49 Million | -21.87% |
| 2005-12-31 | $9.59 Million | +591.15% |
| 2003-12-31 | $1.39 Million | -- |
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinica… Read more